Ms Allan is the Chief Executive Officer of the Lung Foundation Australia, a national charitable organisation that aims to make lung health a priority for all Australians. The CRE-PF will address the significant gap in our understanding of and ability to manage Interstitial Lung Disease. The Lung Foundation, with its expertise in implementing disease-based programs, will provide the critical link to support the translation of research into resources for use by patients, carers, policy makers and clinicians, regardless of their clinical setting.
Prof Anderson is an internationally renowned expert in lung disease research having worked in this field for 2 decades. He is a specialist in translational pharmacology and has particular expertise in the marriage of genetically altered mouse models of disease with human clinical research materials. Prof Anderson founded and is director of the Lung Health Research Centre at University of Melbourne which brings together the leading talent interested in lung disease. He will be involved in advising with regard to the blood and tissue laboratory protocols and will be involved in the CREATE program.
Prof Gibson is a Conjoint Professor of Medicine at the University of Newcastle and a Respiratory Physician at the John Hunter Hospital. He is Co-Director of the Priority Research Centre for Asthma and Respiratory Disease as well as the Vaccines, Immunology, viruses and Asthma group at the Hunter Medical Research Institute. He is also a past President of the Thoracic Society of Australia and New Zealand. Prof Gibson will advise on translational impact and development and implementation of guidelines in the treatment of pulmonary fibrosis.
A/Prof Peter Hopkins is a Thoracic and Transplant physician with a strong research interest and background in interstitial lung disease. He has been the Director of the Queensland Lung Transplant Service since 2007, and has established a state-wide Interventional Bronchoscopy Service and clinical trials centre for patients with idiopathic pulmonary fibrosis. He has been a formative member of the steering committee for the Australian IPF Registry. A/Prof Hopkins is involved in the CRE-PF in his capacity as steering committee member of the IPF Registry, as well as the blood and tissue biobanks, as well as patient recruitment for clinical trials. He is also involved in the CREATE program.
A/Prof Grainge heads the regional clinical Interstitial Lung Disease Service based at John Hunter Hospital, Newcastle. The group is experienced in both basic science research and clinical trials. This group is contributing well-characterised clinical patients, clinical samples and integrated basic science to the study.
Dr Mahar is a consultant histopathologist at the Royal Prince Alfred Hospital, Sydney. Dr Mahar has a special clinical and research interest in respiratory histopathology, and interstitial lung disease in particular. She is a member of the Australian IPF Registry and is involved in this capacity as well as in the review and scoring of all lung biopsies for the registry, and acting in an advisory capacity as a histopathologist.
Dr McCormack is consultant radiologist at Royal Prince Alfred, Sydney. He has a special clinical and research interest in respiratory radiology, and interstitial lung disease in particular. Dr McCormack is involved as the consensus reviewer for HRCT scans for the Australian IPF Registry and acting in an advisory capacity as a radiologist.
Prof Stewart leads the campus-wide interdisciplinary Therapeutic Technologies Hallmark Research Initiative at University of Melbourne and his laboratory conducts studies on target validation and drug discovery in tissue remodelling associated chronic disease. Prof Stewart will supervise graduate researchers conducting studies on biomarker robustness across animal models, organoid human 3D cultures and clinical specimens, qualifying these markers in longitudinal plasma/serum samples, and in biospecimens from the pre-clinical models.